Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic bone marrow-derived mesenchymal stromal cells for steroid-refractory chronic graft-versus-host disease
MOH_2025-01-08_013830Phase 2Recruiting
- Sponsor
- Hadassah Medical Center
- Start
- Aug 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL) in chronic graft-versus-host disease (cGVHD) and graft-versus-host disease (GVHD), sponsored by Hadassah Medical Center. Primary endpoint: Safety. Started Aug 2024; status: recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL)
03
Conditions
chronic graft-versus-host disease (cGVHD)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on MOH_2025-01-08_013830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-01-08_013830.